Fund shareholders of Eledon Pharmaceuticals Inc
ISIN US28617K1016 · United States · LEI 549300S17CAM13O43606
- Fund shareholders
- 104
- Of which ETFs
- 13 91 other funds
- Value held
- ≈ 42.8M $ 42.8M $ · 56.1K €
- Share of capital
- 13.9 % of 81.3M shares on Aug 10, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| SMALL-CAP PROFUND ProFunds | 65 | 219.7 $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 22 | 86.7 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 21 | 80 $ | 0.01 % | 0.00 % | as of May 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 56.1K € | 0.07 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| NVIT GS Small Cap Equity Insights Fund Nationwide Variable Insurance Trust | 0.15 % | as of Jun 30, 2026 ↗ |
| Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund Goldman Sachs Variable Insurance Trust | 0.14 % | as of Jun 30, 2026 ↗ |
| Goldman Sachs Small Cap Growth Insights Fund Goldman Sachs Trust | 0.13 % | as of Jul 31, 2026 ↗ |
| Goldman Sachs Small Cap Equity Insights Fund Goldman Sachs Trust | 0.10 % | as of Jul 31, 2026 ↗ |
| Goldman Sachs Small Cap Value Insights Fund Goldman Sachs Trust | 0.07 % | as of Jul 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.07 % | as of Dec 31, 2025 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.07 % | as of Jun 30, 2026 ↗ |
| AVIP BlackRock Advantage Small Cap Growth Portfolio AuguStar Variable Insurance Products Fund Inc | 0.06 % | as of Jun 30, 2026 ↗ |
| PACE Small/Medium Co Growth Equity Investments PACE SELECT ADVISORS TRUST | 0.04 % | as of Jul 31, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 0.03 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 103 | +12 | 11,268,717 | +18.5 % |
| 2026Q2 | 91 | +14 | 9,511,262 | +25.1 % |
| 2026Q1 | 77 | -8 | 7,604,516 | +6.2 % |
| 2025Q4 | 85 | +15 | 7,158,671 | +4.0 % |
| 2025Q3 | 70 | +46 | 6,885,143 | +71.8 % |
| 2025Q2 | 24 | +6 | 4,006,908 | +15.2 % |
| 2025Q1 | 18 | +5 | 3,476,982 | +70.6 % |
| 2024Q4 | 13 | -2 | 2,038,201 | +46.2 % |
| 2024Q3 | 15 | +5 | 1,393,659 | +20.6 % |
| 2024Q2 | 10 | 0 | 1,155,288 | +31.7 % |
| 2024Q1 | 10 | -1 | 877,429 | +2.9 % |
| 2023Q4 | 11 | 852,639 |
Institutional managers
117 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BVF INC/IL | 6,293,282 | 19.4M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 4,382,245 | 13.5M $ | as of Mar 31, 2026 |
| Defilade Capital Management, L.P. | 3,564,127 | 11M $ | as of Mar 31, 2026 |
| Ensign Peak Advisors, Inc | 2,464,919 | 7.6M $ | as of Mar 31, 2026 |
| Zimmer Partners, LP | 1,875,000 | 5.8M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,791,783 | 5.5M $ | as of Mar 31, 2026 |
| SPHERA FUNDS MANAGEMENT LTD. | 1,772,131 | 5.5M $ | as of Mar 31, 2026 |
| Catalio Capital Management, LP | 1,639,816 | 5.1M $ | as of Mar 31, 2026 |
| Blue Owl Capital Holdings LP | 1,419,912 | 4.4M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 1,154,671 | 3.6M $ | as of Mar 31, 2026 |
| AWM Investment Company, Inc. | 1,100,000 | 3.4M $ | as of Mar 31, 2026 |
| Jefferies Financial Group Inc. | 1,094,456 | 3.4M $ | as of Mar 31, 2026 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,039,275 | 3.2M $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 974,421 | 3M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 869,544 | 2.7M $ | as of Mar 31, 2026 |
| Sanofi | 814,980 | 2.5M $ | as of Mar 31, 2026 |
| CM Management, LLC | 650,000 | 2M $ | as of Mar 31, 2026 |
| 22NW, LP | 636,364 | 2M $ | as of Mar 31, 2026 |
| SG Americas Securities, LLC | 635,845 | 2K $ | as of Mar 31, 2026 |
| UBS Group AG | 547,447 | 1.7M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 543,842 | 1.7M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 370,090 | 1.1M $ | as of Mar 31, 2026 |
| Brevan Howard Capital Management LP | 228,557 | 680K $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 194,022 | 597.6K $ | as of Mar 31, 2026 |
| AQR CAPITAL MANAGEMENT LLC | 172,417 | 531K $ | as of Mar 31, 2026 |
Declared shareholders of Eledon Pharmaceuticals Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Vanguard Capital Management | 5.05 % | 3,898,446 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Eledon Pharmaceuticals Inc". https://titelia.com/en/stocks/eledon-pharmaceuticals-inc-US28617K1016